Todd Harris, CEO of Tyra Biosciences, discusses the company’s experimental oral medicine for achondroplasia, studies conducted to date, and why he believes it will offer competitive advantages over existing therapies. @globalgenes.bsky.social #RARECast globalgenes.org/raredaily/ta...

What happens when AI touches every role, every day, in clinical development? Stephen Pyke of @parexel.bsky.social, in conversation with Nagaraja Srivatsan, highlights why preparing teams early is essential to unlock their full potential. trials?https://www.youtube.com/watch?v=gNTNJhLfzT0&t=1s

Rohan Palekar, CEO of 89bio, discusses what’s driving the prevalence of MASH, the limits of existing medicines, and how the company’s experimental therapy targets both liver fibrosis and the underlying metabolic dysfunctions of the disease. thebioreport.podbean.com/e/a-dual-act...

Paul Peter Tak, president and CEO of Candel Therapeutics, discusses the company's viral immunotherapy for brain cancer, how it works, and what clinical studies have shown to date. @globalgenes.bsky.social #RARECast globalgenes.org/raredaily/65...

Steve Perrin, CSO of Eledon Pharmaceuticals, discusses the need for innovative approaches to immunosuppression in organ transplantation, how its experimental therapy works, and why it may have benefits in autoimmune and neurodegenerative diseases as well. thebioreport.podbean.com/e/extending-...

David Jenkinson of @lifearc.bsky.social discusses the children’s cancer therapeutics consortium C-Further, the challenges of developing treatments for childhood cancers, and why new models for advancing these therapies are needed. @globalgenes.bsky.social #RARECast open.spotify.com/episode/13td...

Mohan Uttarwar, CEO of @1Cell.Ai discusses how AI-powered cell biopsy could make cancer monitoring more accessible, minimally invasive, and transformative for millions of patients worldwide www.agilisium.com/podcast/tran...

Greg Mario, CEO of Taxis Pharmaceuticals, discusses the public health threat posed by drug-resistant gonorrhea, the approaches it’s taking to develop new antimicrobial treatments, and the need for new funding models to bring new therapies to market. thebioreport.podbean.com/e/overcoming...

Robin Williams of UofM Masonic Children's Hospital describes the medical mystery of a 15-year-old who became critically ill when he was admitted into a PICU and what it took to diagnose him with the ultra-rare disease TAFRO. @globalgenes.bsky.social #RARECast globalgenes.org/raredaily/so...

Marc Hedrick, president and CEO of Plus Therapeutics, Inc., discusses the challenges of treating brain tumors, the limitations of current therapies, and why the company’s targeted radiotherapies have the potential to create better outcomes for patients. thebioreport.podbean.com/e/using-targ...

Morten Graugaard, co-founder and CEO of Orbis Medicines, discusses its class of synthetic macrocycles, called nCycles, its platform technology for generating and screening these therapies, and how they can offer an orally delivered alternative to biologics. thebioreport.podbean.com/e/hitting-pr...

Tris Dyson, managing director of Challenge Works, discusses his diagnosis of ALS, the case for using a prize to spur innovation, and the potential for leveraging AI to find treatments for the disease. @globalgenes.bsky.social #RARECast globalgenes.org/raredaily/us...

Stacey Adam of the Foundation for the National Institutes of Health, discusses the public-private partnership she is leading to advance alternatives to animal testing, the technologies they are exploring, and their potential to accelerate drug development. thebioreport.podbean.com/e/building-b...

Daniel Fischer of Tevard Biosciences discusses his journey as the parent of a child with a rare disease, how it led to his co-founding Tevard, and its pursuit of tRNA therapies that may treat a range of diseases with a single drug. @globalgenes.bsky.social #RARECast globalgenes.org/raredaily/re...

Dimitris K. Agrafiotis, Director of Digital Analytics and AI at Arsenal Capital Partners discusses why AI will have a bigger near-term impact on improving operational overhead than on driving novel science. www.agilisium.com/podcast/why-...

Lorin Johnson of Glycyx discusses the effect of opioids on the immune system and the company’s experimental therapy designed to mitigate the negative effects of opioids in cancer patients being treated with checkpoint inhibitors. thebioreport.podbean.com/e/preventing...

Tien Lee, CEO of Aardvark Therapeutics, discusses Prader-Willi syndrome, the biological difference between hunger and appetite, and why his company’s experimental therapy may have broader applications in other forms of obesity. @globalgenes.bsky.social #RARECast globalgenes.org/raredaily/ta...

Abbas Kazimi, CEO Nimbus Therapeutics, discusses how the company’s drug discovery approach has evolved with AI, its deal making successes, and how its business model provides liquidity to investors and while making it easier to structure deals. thebioreport.podbean.com/e/better-liv...

Here's what you may have missed in July from The Bio Report, RARECast, Life Sciences D'n'A, and MitoCast podcasts. www.linkedin.com/pulse/new-ap...

David B. Goldstein, founder and CEO of Actio Biosciences, Inc., discusses the company’s rare-to-common business model, how it identifies the indications it will pursue, and why pricing may represent a challenge. @globalgenes.bsky.social #RARECast globalgenes.org/raredaily/a-...

Juho Jalkanen, founder and CEO of Faron, discusses how the tumor microenvironment can suppress macrophages, how the company’s macrophage checkpoint inhibitor works, and the challenges a Finland-based company faces accessing the capital markets. thebioreport.podbean.com/e/outsmartin...

Bio Usawa and Sartorius have announced a partnership to accelerate Africa’s biopharmaceutical industry and address the continent’s urgent, dual health burdens in infectious and non-communicable diseases. www.globenewswire.com/news-release...

NASA principal investigators Christopher Mason and Afshin Beheshti discuss the impact of space travel on mitochondria, why it represents a critical barrier for space travel, and why solving the problem may give us ways of extending healthy years of life on Earth. www.youtube.com/watch?v=ps4c...

Bio Usawa, a biotechnology company committed to manufacturing affordable monoclonal antibody therapies in Africa, announced a strategic partnership agreement with DEK to distribute Bio Usawa's products throughout Ghana and the broader West African region. www.globenewswire.com/news-release...

Khartik Uppalapati, co-founder of the RareGen Youth Network, discusses his journey as a rare disease patient, his work as an advocate, and why it's essential there be greater youth representation in healthcare policy and advocacy. @globalgenes.bsky.social #RARECast globalgenes.org/raredaily/le...

Sunil Talathi of BeOne Medicines sits down with Nagaraja Srivatsan to discuss his experience implementing AI in a biopharmaceutical company, prompt engineering, and the need for collaboration between humans and AI systems. www.youtube.com/watch?v=5lF_...

Bio Usawa and ServareGMP announced a strategic partnership to establish advanced monoclonal antibody manufacturing capabilities in Africa, directly addressing the critical healthcare access gap affecting patients in low- and middle-income countries. finance.yahoo.com/news/bio-usa...

Arun Upadhyay, CSO and head of R&D at Ocugen, discusses inherited retinal diseases, the company’s gene therapies that can work across different genetic mutations, and the potential of its platform technology beyond the eye. @globalgenes.bsky.social #RARECast globalgenes.org/raredaily/de...

Jenny Marlowe and Melissa Bonner of nChroma Bio discuss the company’s experimental epigenetic editor for hepatitis B, the merger that formed the company, and how it married an epigenetic editing platform with programmable non-viral delivery technologies. thebioreport.podbean.com/e/crafting-a...

Steve Mahoney, CEO of Viridian Therapeutics, discusses thyroid eye disease, the challenges of living with the condition, and why its veligrotug has the potential to provide a new alternative for people living with the condition. @globalgenes.bsky.social #RARECast globalgenes.org/raredaily/ey...

Craig Lipset, advisor and founder of Clinical Innovation Partners, discusses how AI can bring greater predictability to clinical trials, how organizations can effectively adopt the technology, and the importance of fostering a culture of experimentation. www.youtube.com/watch?v=Ka3U...

Niven Narain, CEO of BPGbio, discusses how the company’s platform technology uncovers novel targets, its evolution from its start as Berg, and how the platform continues to provide insight into experimental therapies after they advance to the clinic. thebioreport.podbean.com/e/fueling-ai...

Traci Davies and her son Ben Davies both discuss their experiences with primary immunodeficiency, what it’s like to be both a caregiver and patient, and why they have both become patient advocates. @globalgenes.bsky.social #RARECast globalgenes.org/raredaily/li...

Here's what you may have missed in June from The Bio Report, RARECast, and the Life Sciences D'n'A podcasts. www.linkedin.com/pulse/turboc...

Bio Usawa and Bioeq AG announce a groundbreaking agreement to bring a life-changing biosimilar medicine—ranibizumab, used to treat serious retinal diseases—within reach for millions across Sub-Saharan Africa. www.globenewswire.com/news-release...

Melanie Kandzierski discusses how she has learned to care for a child with Dravet syndrome, care for herself, and to advocate not only for her child but others with complex medical conditions. @globalgenes.bsky.social #RARECast globalgenes.org/raredaily/tr...

Ariel Katz, co-founder and CEO of H1, discusses the unique dataset behind the company’s platform to connect life sciences companies to healthcare providers, the problem it solves for biopharmaceutical companies, and some unexpected ways the platform has been used. www.youtube.com/watch?v=tPHL...

Steve Ruston, CEO of Persica Pharmaceuticals, discusses the need for new approaches to chronic low back pain, the company’s experimental targeted antibiotic injections, and the need to educate physicians about the role infection can play in the condition. thebioreport.podbean.com/e/a-novel-ap...

Patrick Ritschel of Atsena Tx discusses the delivery challenges of gene therapies for inherited retinal diseases, how the company’s vector technology addresses this, and how it allows for safer and more effective delivery. @globalgenes.bsky.social #RARECast globalgenes.org/raredaily/ov...

Barry Quart, CEO of Connect Biopharma, discusses the unmet need in asthma and COPD, the company’s experimental therapy rademikibart, and the case for a biologic that can address acute exacerbations of these conditions. thebioreport.podbean.com/e/a-biologic...

P.J. Brooks of NIH's NCATS discusses the recent treatment of an infant with a bespoke gene editing therapy, how researchers were able to move from diagnosis to treatment with great speed, and what it would take to scale such an approach. @globalgenes.bsky.social globalgenes.org/raredaily/a-...

Venky Iyer, director of data strategy and automation at Pfizer, discusses his journey in implementing AI solutions to enhance operational efficiency at Pfizer, the importance of managing change, and the value of AI adoption in improving drug development processes. www.youtube.com/watch?v=ZFbf...

Leeland Ekstrom of Nashbio, discusses its founding as a for-profit subsidiary of Vanderbilt University Medical Center, the significance its alliance with leading biopharma cos, and how it's enabling a transformation of drug development with data. thebioreport.podbean.com/e/turbocharg...

Annette Bakker, CEO of the Children's Tumor Foundation, discusses the complexities of neurofibromatosis, the foundation’s role in advancing research and drug development, and what other patient organizations can learn from its approach. @globalgenes.bsky.social globalgenes.org/raredaily/ho...

Lumen Bioscience's Brian Finrow discusses his company’s platform technology for engineering spirulina to produce biologics, why it makes possible orally-delivered protein therapeutics, and how it can make advanced therapies more affordable and accessible. thebioreport.podbean.com/e/revolution...

Here's what you may have missed in May from The Bio Report, RARECast, and Life Sciences D'n'A podcasts. www.linkedin.com/pulse/cuttin...

Amber Salzman, CEO of Epicrispr Biotechnologies, discusses how the company’s one-and-done therapies work to target the epigenome, its lead program in FSHD, and the broader applications for its therapeutic approach. @globalgenes.bsky.social #RARECast globalgenes.org/raredaily/us...

Scott Chetham, co-founder and CEO of Faro Health, discusses how AI can enhance patient selection, feasibility assessments, and protocol writing to accelerate drug development cost-effectively. www.youtube.com/watch?v=THpk...

Matthew Shaulis, general manager of North America for BeOne Medicines, discusses the significant global disparities in cancer care, and the opportunities and challenges of taking a global approach to marketing innovative medicines. thebioreport.podbean.com/e/making-med...

Anish Bhatnagar, CEO of Soleno Therapeutics, discusses Prader-Willi syndrome, the company’s therapy to treat the condition, and the significance of having a medicine that can address hyperphagia associated with the disorder. @globalgenes.bsky.social #RARECast globalgenes.org/raredaily/sa...